🧪 Peptide Drugs - CWhiting

🥗Nutrition Academic

nature.com·

[Comment] Multireceptor modulation in metabolic disease: are more targets better?

🧠Gut-Brain Axis

thelancet.com·

expert reaction to two studies looking at AstraZeneca’s GLP 1 pill, elecoglipron, for reducing weight and lowering blood-sugar in adults with and without type 2 diabetes

📰HBR

sciencemediacentre.org·

Less-relevant results

Colostrum: the beauty ingredient Rosé from Blackpink and Dua Lipa swear by

🌿Lifestyle News

scmp.com·

Up-to-Date Evidence Reviews of Health and Longevity Interventions

🥗Nutrition

evipedia.ai··Hacker News

Active Flow Expansion for Out-of-Distribution Discovery: from Theory to Molecules

⚗️Generative Chemistry Academic

arxiv.org·

15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist–induced weight loss

😴Recovery Science

pnas.org·

[Articles] Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo...

⏰Circadian Eating

thelancet.com·

Scientists Turn Hookworms Into Living Pharmacies That Can Deliver Medicine From Inside Humans

🏥Future of Medicine

zmescience.com·

Drug apitegromab may stop muscle loss when taking weight loss drugs

🔬Breakthroughs

medicalxpress.com·

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

💡Invention

lifestyle.bombreport.com·

The Scale Moves, the Mirror Doesn’t: Why GLP-1 Weight Loss Leaves the Mind Behind

🩺Health

easternherald.com·

[Articles] Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-c...

⏰Circadian Eating

thelancet.com·

[Comment] Can oral GLP-1 receptor agonists ACHIEVE the same as SGLT2 inhibitors?

⏰Chrononutrition

thelancet.com·

[Articles] Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, r...

⏰Chrononutrition

thelancet.com·

GLP-1-based meds are linked to fewer heart events in adults with obesity, autoimmune disease

🔬Tech & Science

medicalxpress.com·

[Comment] Treatment potential of oral small-molecule GLP-1 receptor agonists

⏰Circadian Eating

thelancet.com·

Weight loss treatments linked to lower risk of obesity-related cancers in people without diabetes

🔬Tech & Science

medicalxpress.com·

[Articles] Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-...

⏰Chrononutrition

thelancet.com·

New GLP-1 oral pill lowers blood sugar and reduces bodyweight, clinical trial finds

Is the peptide craze backed by science? The promise behind the hype

[Comment] Multireceptor modulation in metabolic disease: are more targets better?

expert reaction to two studies looking at AstraZeneca’s GLP 1 pill, elecoglipron, for reducing weight and lowering blood-sugar in adults with and without type 2 diabetes

Colostrum: the beauty ingredient Rosé from Blackpink and Dua Lipa swear by

Up-to-Date Evidence Reviews of Health and Longevity Interventions

Active Flow Expansion for Out-of-Distribution Discovery: from Theory to Molecules

15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist–induced weight loss

[Articles] Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo...

Scientists Turn Hookworms Into Living Pharmacies That Can Deliver Medicine From Inside Humans

Drug apitegromab may stop muscle loss when taking weight loss drugs

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

The Scale Moves, the Mirror Doesn’t: Why GLP-1 Weight Loss Leaves the Mind Behind

[Articles] Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-c...

[Comment] Can oral GLP-1 receptor agonists ACHIEVE the same as SGLT2 inhibitors?

[Articles] Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, r...

GLP-1-based meds are linked to fewer heart events in adults with obesity, autoimmune disease

[Comment] Treatment potential of oral small-molecule GLP-1 receptor agonists

Weight loss treatments linked to lower risk of obesity-related cancers in people without diabetes

[Articles] Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-...